Trials / Terminated
TerminatedNCT00851448
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients. A Randomised, Double-blind, Controlled Pilot Study
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Fresenius Kabi · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and anorexia in lung cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | oral nutritional supplement, food for special medical purposes | 2 servings of 200-300 ml per day, treatment period: 16 weeks |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2009-02-26
- Last updated
- 2011-06-02
Locations
3 sites across 2 countries: Italy, Poland
Source: ClinicalTrials.gov record NCT00851448. Inclusion in this directory is not an endorsement.